

CORRECTION

# Correction: Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma

The *PLOS ONE* Staff

## Notice of Republication

This article was republished on August 14, 2018, to correct for errors in the Data Availability statement introduced during the production process. The publisher apologizes for the errors. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.

## Supporting information

**S1 File. Originally published, uncorrected article.**


(PDF)

**S2 File. Republished, corrected article.**

(PDF)

## Reference

1. Azuma T, Sato Y, Ohno T, Azuma M, Kume H (2018) Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma. *PLoS ONE* 13(7): e0199719. <https://doi.org/10.1371/journal.pone.0199719> PMID: 30044793



## OPEN ACCESS

**Citation:** The *PLOS ONE* Staff (2018) Correction: Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma. *PLoS ONE* 13(8): e0203174. <https://doi.org/10.1371/journal.pone.0203174>

**Published:** August 23, 2018

**Copyright:** © 2018 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.